However, some studies propose that Aβ-independent factors, such as genetic risk and metabolic pathways, can also regulate tau pathology in AD models, including transgenic mice and patient-derived human induced pluripotent stem cell (iPSC) models [17, 18]. Here, MAPT is linked to Alzheimer disease.